People: CRISPR Therapeutics AG (CRSP.OQ)
25 Apr 2019
Dr. Bradley J. (Brad) Bolzon, Ph.D., has been Independent Director of CRISPR Therapeutics Ltd since November 2013. He has more than 13 years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing, with a particular emphasis on new company start-ups. Prior to joining Versant, he served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, he held executive roles at Lilly in drug discovery, clinical research, regulatory affairs and business development. He received his Ph.D. and an M.S. in pharmacology from the University of Toronto. He conducted his post-doctoral research training at the Ottawa Heart Institute in Ottawa, Canada.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|